Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB03891"

PredicateValue (sorted: default)
rdfs:label
"1,5-Bis(N-Benzyloxycarbonyl-L-Leucinyl)Carbohydrazide"
rdf:type
drugbank:description
" experimental This compound belongs to the n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at his terminal nitrogen atom. N-acyl-alpha Amino Acids and Derivatives Organic Compounds Organic Acids and Derivatives Carboxylic Acids and Derivatives Amino Acids, Peptides, and Analogues Alpha Amino Acid Amides Benzyloxycarbonyls Benzylethers Dicarboxylic Acids and Derivatives Semicarbazides Carboxylic Acid Hydrazides Carbamic Acids and Derivatives Carboxylic Acid Amides Ethers Polyamines Enolates benzyloxycarbonyl benzylether dicarboxylic acid derivative benzene semicarbazide carboxamide group carboxylic acid hydrazide carbamic acid derivative polyamine ether enolate hydrazine derivative amine organonitrogen compound logP 2.07 ALOGPS logS -5.2 ALOGPS Water Solubility 4.06e-03 g/l ALOGPS logP 3.58 ChemAxon IUPAC Name benzyl N-[(1R)-1-[({[(2R)-2-{[(benzyloxy)carbonyl]amino}-4-methylpentanehydrazido]carbonyl}amino)carbamoyl]-3-methylbutyl]carbamate ChemAxon Traditional IUPAC Name benzyl N-[(1R)-1-[({[(2R)-2-{[(benzyloxy)carbonyl]amino}-4-methylpentanehydrazido]carbonyl}amino)carbamoyl]-3-methylbutyl]carbamate ChemAxon Molecular Weight 584.6639 ChemAxon Monoisotopic Weight 584.295847664 ChemAxon SMILES CC(C)C[C@@H](NC(=O)OCC1=CC=CC=C1)C(=O)NNC(=O)NNC(=O)[C@@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 ChemAxon Molecular Formula C29H40N6O7 ChemAxon InChI InChI=1S/C29H40N6O7/c1-19(2)15-23(30-28(39)41-17-21-11-7-5-8-12-21)25(36)32-34-27(38)35-33-26(37)24(16-20(3)4)31-29(40)42-18-22-13-9-6-10-14-22/h5-14,19-20,23-24H,15-18H2,1-4H3,(H,30,39)(H,31,40)(H,32,36)(H,33,37)(H2,34,35,38)/t23-,24-/m1/s1 ChemAxon InChIKey InChIKey=HGDUWJVGIGLVOH-DNQXCXABSA-N ChemAxon Polar Surface Area (PSA) 175.99 ChemAxon Refractivity 153.29 ChemAxon Polarizability 61.99 ChemAxon Rotatable Bond Count 16 ChemAxon H Bond Acceptor Count 5 ChemAxon H Bond Donor Count 6 ChemAxon pKa (strongest acidic) 9.26 ChemAxon Physiological Charge 0 ChemAxon Number of Rings 2 ChemAxon Bioavailability 0 ChemAxon PubChem Compound 46936822 PubChem Substance 46505828 PDB INA BE0003417 Cathepsin K Human # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 # Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10592235 unknown Cathepsin K Involved in cysteine-type endopeptidase activity Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation CTSK 1q21 Lysosome None 8.65 36966.0 Human HUGO Gene Nomenclature Committee (HGNC) HGNC:2536 GenAtlas CTSK GenBank Gene Database U13665 UniProtKB P43235 UniProt Accession CATK_HUMAN Cathepsin K precursor Cathepsin O Cathepsin O2 Cathepsin X EC 3.4.22.38 >Cathepsin K MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEISRRLIWEKNLKYISIH NLEASLGVHTYELAMNHLGDMTSEEVVQKMTGLKVPLSHSRSNDTLYIPEWEGRAPDSVD YRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGG YMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVA RVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGE NWGNKGYILMARNKNNACGIANLASFPKM >990 bp ATGTGGGGGCTCAAGGTTCTGCTGCTACCTGTGGTGAGCTTTGCTCTGTACCCTGAGGAG ATACTGGACACCCACTGGGAGCTATGGAAGAAGACCCACAGGAAGCAATATAACAACAAG GTGGATGAAATCTCTCGGCGTTTAATTTGGGAAAAAAACCTGAAGTATATTTCCATCCAT AACCTTGAGGCTTCTCTTGGTGTCCATACATATGAACTGGCTATGAACCACCTGGGGGAC ATGACCAGTGAAGAGGTGGTTCAGAAGATGACTGGACTCAAAGTACCCCTGTCTCATTCC CGCAGTAATGACACCCTTTATATCCCAGAATGGGAAGGTAGAGCCCCAGACTCTGTCGAC TATCGAAAGAAAGGATATGTTACTCCTGTCAAAAATCAGGGTCAGTGTGGTTCCTGTTGG GCTTTTAGCTCTGTGGGTGCCCTGGAGGGCCAACTCAAGAAGAAAACTGGCAAACTCTTA AATCTGAGTCCCCAGAACCTAGTGGATTGTGTGTCTGAGAATGATGGCTGTGGAGGGGGC TACATGACCAATGCCTTCCAATATGTGCAGAAGAACCGGGGTATTGACTCTGAAGATGCC TACCCATATGTGGGACAGGAAGAGAGTTGTATGTACAACCCAACAGGCAAGGCAGCTAAA TGCAGAGGGTACAGAGAGATCCCCGAGGGGAATGAGAAAGCCCTGAAGAGGGCAGTGGCC CGAGTGGGACCTGTCTCTGTGGCCATTGATGCAAGCCTGACCTCCTTCCAGTTTTACAGC AAAGGTGTGTATTATGATGAAAGCTGCAATAGCGATAATCTGAACCATGCGGTTTTGGCA GTGGGATATGGAATCCAGAAGGGAAACAAGCACTGGATAATTAAAAACAGCTGGGGAGAA AACTGGGGAAACAAAGGATATATCCTCATGGCTCGAAATAAGAACAACGCCTGTGGCATT GCCAACCTGGCCAGCTTCCCCAAGATGTGA PF00112 Peptidase_C1 PF08246 Inhibitor_I29 function peptidase activity function endopeptidase activity function cysteine-type endopeptidase activity function cysteine-type peptidase activity function catalytic activity function hydrolase activity process cellular protein metabolism process proteolysis process physiological process process metabolism process macromolecule metabolism process protein metabolism "
owl:sameAs

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines2/drugbank_small.nt

The resource does not appear as an object

Context graph